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The optimal combination of hemodialysis (HD) dose and
session length remains uncertain, and previous studies have
not conclusively shown session length to be an important
independent determinant of patient mortality. The objective
of this study was to examine associations between HD dose
and session length with mortality risk using data from the
Australian and New Zealand Dialysis and Transplant Registry.
Analyses were performed using a prospective inception
cohort comprising all incident adult patients treated by
thrice-weekly maintenance HD, who commenced renal
replacement therapy with HD between 1 April 1997 and 31
March 2004. In all, 6593 patients were identified, of whom
4193 had sufficient data for multivariate analyses. HD dose
(single pool fractional clearance of urea, Kt/V) and session
length were included in analyses as those recorded
12 months after HD inception to reduce confounding by
residual renal function. The outcome examined was patient
mortality. Survival analyses included Kaplan–Meier
calculations of survival and Cox regression for multivariate
analyses. Covariates in Cox models included patient
demographics, co-morbid medical conditions at HD
inception, and HD operating parameters. After adjustment
for covariates and each other, Kt/V of 1.30–1.39 and session
length of 4.5–4.9 h were associated with the lowest mortality
risk. There was no interaction between HD dose and session
length. Thus, the optimal combination for mortality appears
to be Kt/V of X1.3 and session length of X4.5 h. These
data suggest a randomized controlled trial to test these
hypotheses, and support the inclusion of criteria relating
to session length in definitions of adequate HD practice.
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The annual mortality rate in hemodialysis (HD) populations
is unacceptably high. In the United States (US), it remains
consistently higher than that in other developed nations. It
has been recently reported that approximately 30% of this
increased mortality risk in the US compared to elsewhere is
attributable to more severe co-morbid medical burden and
older age.1 The majority of this increased risk is therefore
likely to result from HD practice patterns. There is in general
a lack of critical evidence governing such practice, and
adequate HD remains difficult to define and is to a large
degree opinion-based. With such accessible and well-defined
patients, there is an urgent need for further study to improve
outcomes in this population.
The interrelated effects of HD dose and session length on
patient outcomes have never been satisfactorily resolved.
Interest in this area has remained high, especially after the
publication of the Hemodialysis (HEMO) Study, which
showed that outcomes were not improved with higher doses
of dialysis than current consensus standards for patients
receiving HD on a conventional short-hour thrice-weekly
schedule.2 One implication of this study is that further
improvement in outcomes might necessarily involve more
than simply change to dialysis operating parameters within
the limitations of this particular schedule.3 Increasingly,
clinical outcomes research is focusing on unconventional HD
regimens characterized by varying combinations of high and
low efficiency, longer and shorter session length, and hemeral
or nocturnal schedule. Simulations and limited clinical data
have determined the impact of these different regimens upon
solute control.4–7 However, there is only limited information
regarding clinical outcomes, with most series published
out of single centers and none from large multi-center
observational datasets.4,5,8–10 There is even less known
about the optimal HD session length for the thrice-weekly
schedule, which is likely to remain the schedule for most HD
patients unless studies of unconventional regimens yield
conclusive results, and resources are made available to
implement them.
The most conspicuous features of HD delivery in the US
have historically been low HD dose and short session length.
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Recent data indicate that HD dose is no longer disparate
between the US and elsewhere, although HD sessions remain
short.11,12 In Australia and New Zealand, HD practice
patterns have evolved independently of the fiscal regulations
that have shaped corresponding practice in the US. There is
greater variation in HD dose and session length in Australia
and New Zealand, and this may allow for the identification of
different associations between these parameters and patient
outcomes. The objective of this study was to determine the
association between both HD dose and session length with
mortality risk in a large HD population receiving thrice-
weekly treatments, using data from the Australian and New
Zealand Dialysis and Transplant (ANZDATA) Registry.
RESULTS
Cohort description
In all, 6593 adult patients were identified as being treated
with maintenance thrice-weekly HD (on HD both 90 days
after commencement and also at 12 months after dialysis
inception) in Australia and New Zealand between 1 April
1997 and 31 March 2004. Of these, 4171 patients had
sufficient data to be included in modelling. Table 1
summarizes the characteristics of both cohorts. The study
cohort was representative of the inception cohort except in
two regards. The study cohort had a slightly lower proportion
of patients whose primary renal disease was glomerulo-
nephritis, and contained slightly older patients. Among the
study cohort, there were 984 deaths recorded over 7228
person-years of follow-up. Of the deaths, 51% were
attributed to cardiovascular disease, 12% to infections, and
13% to voluntary dialysis withdrawal.
Relationship between HD dose and session length
The distributions of HD dose and session length within the
study cohort are shown in Figure 1. These parameters were
not correlated (r¼ 0.027, P¼ 0.08). Figure 2 illustrates HD
session length stratified by Kt/V for the study cohort. There
was no evidence for an interaction between HD session
length and Kt/V in any of the analyses, and each parameter
was therefore analyzed separately.
HD dose
The most prevalent Kt/V category was X1.4. Univariate and
multivariate analyses are presented in Table 2. Hazard ratios
derived from the final multivariate model are shown in
Figure 3. Hemodialyser flux, body mass index, cerebrovascular
disease and chronic lung disease were not found to be
significant and independent covariates, and were therefore not
included in the multivariate model. After adjustment for
patient demographics and co-morbid conditions, Kt/V of
1.30–1.39 was associated with the lowest mortality risk. When
further adjusted for HD session length, the relationship
between mortality and dose persisted, suggesting that the
mechanism for the lower mortality risk with higher Kt/V was
not primarily longer session lengths. The fractional polynomial
analyses (Figure 4) were similar to the categorical analysis.
HD session length
The most prevalent HD session length category was 4.0–4.4 h.
Univariate and multivariate analyses are presented in Table 3.
After adjustment for patient demographics and co-morbid
medical conditions, session length of 4.5–4.9 h was associated
Table 1 | Clinical characteristics of patients
Variable
Inception
cohort (%)
Study
cohort (%)
Number 6593 4171
Country
Australia 5781 (87.7) 3700 (88.7)
New Zealand 812 (12.3) 471 (11.3)
Age (years) (median, IQR) 58.2 (46.2–68.7) 59.9 (48.3–70.7)a
Gender
Male 4093 (62.1) 2570 (61.6)
Female 2500 (37.9) 1601 (38.4)
Race
Caucasian/other 5133 (77.8) 3215 (77.9)
Aboriginal/Torres Islander 598 (9.1) 419 (10.0)
Asian 359 (5.5) 217 (5.2)
Maori/Pacific Islander 503 (7.6) 320 (7.7)
Late referralb 1600 (24.3) 1046 (25.1)
Smoking
Current 929 (14.1) 568 (13.6)
Former 2712 (41.1) 1759 (42.2)
Diabetes mellitus
Type 1 228 (3.5) 143 (3.4)
Type 2 2087 (31.7) 1442 (34.6)
Primary renal disease
Glomerulonephritis 1967 (29.8) 1127 (27.0)c
Analgesic nephropathy 282 (4.3) 169 (4.1)
Hypertension/ischemic
nephropathy
855 (13.0) 600 (14.4)
Polycystic kidney disease 509 (7.7) 279 (6.7)
Diabetic nephropathy 1701 (25.8) 1153 (27.6)
Other 1279 (19.4) 843 (20.2)
Coronary artery disease 2484 (37.7) 1646 (39.5)
Peripheral vascular disease 1659 (25.2) 1084 (26.0)
Cerebrovascular disease 898 (13.6) 594 (14.2)
Treated hypertension 5742 (87.1) 3620 (86.8)
Lung disease 968 (14.7) 631 (15.1)
BMI (kg/m2) (median, IQR) 26.0 (22.8–30.1) 25.3 (22.4–29.0)a
Hemodialyser flux
Low 5710 (86.6) 3465 (83.1)
High 883 (13.4) 706 (16.9)
Dialysis accessd
Arteriovenous fistula 3786 (77.4) 3223 (77.3)
Arteriovenous graft 706 (10.7) 589 (14.1)
Central venous catheter 456 (6.9) 359 (8.6)
BMI, body mass index; IQR, interquartile range.
aPo0.001 and refer to the difference between the inception and study cohorts.
bReferral for nephrology pre dialysis care o3 months before dialysis inception.
cPo0.05.
dThere were 1645 missing responses.
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with the lowest mortality risk, ando3.5 h the highest. When
further adjusted for HD dose, the relationship between
session length and mortality persisted, suggesting that the
mechanism for the lower mortality risk with session length of
4.5–4.9 h was not primarily larger dose among HD patients
receiving longer sessions. The fractional polynomial analyses
(Figure 4) were similar to the categorical analysis; whether
the mortality risk in the X5 h group was further reduced
could not be established due to insufficient power.
Characteristics of the study cohort for those treated with
long (X4.5 h) versus short (o4.5 h) sessions are presented in
Table 4, and in general those receiving longer HD treatments
were more likely to be larger, younger, male, current smokers,
of Aboriginal, Maori, and Torres Strait and Pacific Island
descent, and have diabetes mellitus. We specifically sought,
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Figure 1 | Distribution of HD session length and dose within the
study cohort.
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Figure 2 | Distribution of HD session length by categories of Kt/V.
Table 2 | Mortality risk according to HD dose category
Model
HD dose
Kt/V (n)
Hazard ratio
(95% confidence
intervals)
Univariate o1.0 (161) 1.59 (0.17–2.17)a
1.0–1.19 (705) 0.99 (0.81–1.20)
1.20–1.29 (857) 1.00 (Ref)
1.30–1.39 (1072) 0.79 (0.65–0.95)b
X1.4 (1376) 0.92 (0.77–1.1)
Multivariate (excluding adjustment
for HD session length)
o1.0 (161) 1.42 (1.03–1.96)b
1.0–1.19 (705) 1.03 (0.84–1.25)
1.20–1.29 (857) 1.00 (Ref)
1.30–1.39 (1072) 0.79 (0.69–0.99)a
X1.4 (1376) 1.42 (1.03–1.96)b
Adjusted for HD session length
Univariate o1.0 (161) 1.54 (1.13–2.11)a
1.0–1.19 (705) 0.97 (0.79–1.18)
1.20–1.29 (857) 1.00 (Ref)
1.30–1.39 (1072) 0.79 (0.66–0.96)c
X1.4 (1376) 0.89 (0.75–1.06)
Multivariate o1.0 (161) 1.42 (1.03–1.97)a
1.0–1.19 (705) 1.03 (0.84–1.25)
1.20–1.29 (857) 1.00 (Ref)
1.30–1.39 (1072) 0.79 (0.65–0.95)c
X1.4 (1376) 0.83 (0.69–0.99)c
HD, hemodialysis.
aPo0.01.
bPo0.001.
cPo0.05.
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Figure 3 | Hazard ratios for mortality within study cohort
according to selected predictive variables. Hazard ratios were
derived within a multivariate Cox proportional-hazard model, with
shared frailty for each treatment centre. Asterisks indicate the
reference categories. Horizontal bars indicate 95% confidence
intervals.
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but could not formally demonstrate, a statistical interaction
between session length and body mass index (BMI) in the
final regression model (interaction HD session lengthBMI
P¼ 0.22). The issue was further explored by creating
categories allowing comparisons of all combinations of
BMI categories and session length in the multivariate model
(Figure 5). Examined in this manner, the association of
longer HD sessions with reduced mortality was seen among
those in middle and higher BMI groups, but not in the lowest
BMI group.
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Figure 4 | Univariate and multivariate fractional polynomial
graphs depicting the relationship between both HD session
length and dose with mortality risk. The multivariate graphs are
fully adjusted for patient demographic and co-morbid medical
conditions, and HD session length and dose in the other’s respective
analyses. Shaded areas indicate 95% confidence intervals.
Table 3 | Mortality risk according to HD session length
category
Model
HD session
length in
hours (n)
Hazard ratio
(95% confidence
intervals)
Univariate o3.5 (121) 1.75 (1.27–2.40)a
3.5–3.9 (187) 1.18 (0.88–1.60)
4–4.4 (2091) 1.00 (Ref)
4.5–4.9 (753) 0.71 (0.59–0.86)a
X5 (1019) 0.72 (0.60–0.86)a
Multivariate (excluding
adjustment for Kt/V)
o3.5 (121) 1.69 (1.23–2.32)b
3.5–3.9 (187) 1.11 (0.83–1.48)
4–4.4 (2091) 1.00 (Ref)
4.5–4.9 (753) 0.79 (0.65–0.96)c
X5 (1019) 0.99 (0.82–1.18)
Adjusted for HD dose
Univariate o3.5 (121) 1.67 (1.22–2.31)b
3.5–3.9 (187) 1.19 (0.88–1.60)
4–4.4 (2091) 1.00 (Ref)
4.5–4.9 (753) 0.71 (0.59–0.85)a
X5 (1019) 0.71 (0.59–0.86)a
Multivariate o3.5 (121) 1.57 (1.14–2.17)b
3.5–3.9 (187) 1.09 (0.81–1.46)
4–4.4 (2091) 1.00 (Ref)
4.5–4.9 (753) 0.80 (0.66–0.97)c
X5 (1019) 1.02 (0.85–1.22)
HD, hemodialysis.
aPo0.001.
bPo0.01.
cPo0.05.
Table 4 | Clinical characteristics of the study cohort compared
by HD session length category
Variable o4.5 h (%) X4.5 h (%)
Number 2399 1722
Country
Australia 2191 (91.3) 1509 (85.2)a
New Zealand 208 (8.7) 263 (14.8)
Age (years) (median, IQR) 65.4 (53.2–73.6) 58.1 (47.1–68.2)a
Gender
Male 1299 (54.1) 1271 (71.7)a
Female 1100 (45.9) 501 (28.3)
Race
Caucasian/other 1999 (83.3) 1216 (68.6)a
Aboriginal/Torres Islander 152 (6.3) 267 (15.1)
Asian 137 (5.7) 80 (4.5)
Maori/Pacific Islander 111 (4.6) 209 (11.8)
Late referralb 566 (23.6) 480 (27.1)c
Smoking
Current 301 (12.6) 267 (15.1)a
Former 976 (40.7) 783 (44.2)
Diabetes mellitus
Type 1 87 (3.6) 56 (3.2)a
Type 2 699 (29.1) 742 (41.9)
Primary renal disease
Glomerulonephritis 623 (26.0) 504 (28.4)a
Analgesic nephropathy 119 (5.0) 50 (2.8)
Hypertension/ischemic nephropathy 412 (17.2) 188 (10.6)
Polycystic kidney disease 155 (6.5) 124 (7.0)
Diabetic nephropathy 562 (23.4) 591 (33.4)
Other 528 (22.0) 315 (17.8)
Coronary artery disease 979 (40.8) 667 (37.6)c
Peripheral vascular disease 617 (25.7) 467 (26.4)
Cerebrovascular disease 343 (14.3) 251 (14.2)
Treated hypertension 2399 (85.9) 1559 (87.9)
Lung disease 363 (15.1) 268 (15.1)
BMI (kg/m2) (median, IQR) 24.9 (22.0–28.6) 27.8 (24.2–32.4)a
Hemodialyser flux
Low 2030 (84.6) 1435 (81.0)d
High 369 (15.4) 337 (19.0)
Dialysis accesse
Arteriovenous fistula 1832 (76.4) 1391 (78.5)d
Arteriovenous graft 332 (13.8) 257 (14.5)
Central venous catheter 235 (9.8) 124 (7.0)
BMI, body mass index; IQR, interquartile range.
aPo0.001 and refer to the difference between the subgroups receiving longer and
shorter HD treatments.
bReferral for nephrology pre dialysis care o3 months before dialysis inception.
cPo0.05.
dPo0.01.
eThere were 1645 missing responses.
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DISCUSSION
It seems axiomatic that more dialysis should provide better
outcomes, and there are few who would consider uremic
toxicity to be abrogated by the current standard of short-
hour thrice-weekly HD. However, optimal HD practice does
remain uncertain. There is expert consensus about HD dose
in the Kidney Disease Outcomes Quality Initiative and
European Best Practice Guidelines,13,14 and also in the Caring
for Australians with Renal Impairment guidelines under
development for Australian and New Zealand chronic kidney
disease patients (www.kidney.org.au/cari). In contrast, there
is no such consensus about HD session length. The
recommendations of the Caring for Australians with Renal
Impairment guidelines for well-powered, statistically robust
observational analyses have led to these analyses of the
ANZDATA Registry.
The findings of this study support the minimum
standards for HD dose advocated by the aforementioned
consensus guidelines. However, the crucial finding in this
study was that shorter HD session length was associated with
higher mortality risk, independently of HD dose. This
implies that the evaluation of dialysis adequacy by HD dose
alone may be insufficient to optimize outcomes, and that
adequate dialysis may be characterized by HD session length
of 4.5 h or longer, irrespective of dose. This paradigm has
enormous implications for both HD providers and patients.
The relative effects of HD dose and session length on
patient outcomes were originally explored in the National
Cooperative Dialysis Study.15 This study showed that small
solute control was a more important determinant of patient
morbidity than HD session length. The study did in fact
suggest a causal relationship between shorter dialysis and
excess patient morbidity, although it was not sufficiently
different from chance (P¼ 0.056) to be regarded as
significant. As a result, HD session length has often not
been considered by both researchers and clinicians in the
endeavor to define and deliver adequate dialysis.
To our knowledge, there have been no studies other than
the National Cooperative Dialysis Study that have addressed
the issue of HD dose and session length in a definitive
manner. However, a number of observational studies have
provided support for both dose and length as determinants
of patient mortality. Single-center experience from Tassin,
France has shown superior surrogate and actual patient
outcomes with longer HD session lengths.16,17 The most
compelling multi-center observations have been made using
registry-sourced data from a 1993 Japanese cohort, in which
HD session length of 5.0–5.5 h was shown to be indepen-
dently associated with the lowest mortality risk (Po0.01),
even when analyses were adjusted for Kt/V.18 Observations
more applicable to US and European populations have been
made using US patient cohorts from the 1980s, including two
studies in which HD session length shorter than 3.5 h was
independently associated with up to approximately doubled
mortality risk compared to longer sessions, although neither
analysis was adjusted for HD dose.19,20 Most recently, the
Dialysis Outcome and Practice Patterns Study has presented
various analyses using a large cohort of Japanese, US and
European patients, in which HD session length shorter than
3.5 h was shown to be independently associated with a 33%
higher mortality risk (P¼ 0.004), even when analyses were
adjusted for Kt/V.21
The data from this study confirm that HD delivery in
Australia and New Zealand is characterized by relatively high
delivered HD dose, achieved by longer HD treatments rather
than higher blood flow rates. HD session length averaged
263 min and blood flow rate 294 ml/min, as compared with
213 min and 401 ml/min in the US and 234 min and 296 ml/
min in Europe.12,22 This HD practice pattern can be
attributed to two factors particular to Australia and New
Zealand. Firstly, the higher prevalence of home hemodialysis
in Australia and New Zealand (stable at approximately 14 and
25% of HD patients, respectively23) may potentially dilute
the effect of scheduling restraints within facilities that so
often lead to shortening of hours. Secondly, the prevailing
opinion among nephrologists in Australia and New Zealand
is that HD session length is at least as, if not more, important
than dose: many centers do not prescribe HD treatments of
less than 5 h, and those dialyzing their patients for longer
hours often do not measure HD dose.
There are several possible mechanisms for improved
outcomes with longer sessions. Importantly, our analyses
have confirmed that the effect of longer HD session length on
mortality in this study was not as a result of statistical
confounding by BMI. If anything, the effect of session length
is more marked among those with higher BMI. Other studies
have shown that longer HD sessions result in greater removal
of larger molecules,7 and improved phosphate and bicarbo-
nate control,24 even for a given amount of small solute
removal.25–27 In addition, less intradialytic hemodynamic
instability allows more consistent achievement of dry weight,
better blood pressure control, and probably less sympathetic
hyperactivity.28,29 Despite these findings, it is important to
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Figure 5 | Hazard ratios (HR) for mortality by HD session length
and body mass index (BMI). The multivariate analyses are fully
adjusted using the final regression model. All HR are relative to the
group with BMI 25–29 and session length 4.5–4.9 h. Mortality risk is
the same for different session lengths in group with BMI o25
(P¼ 0.85), although differences are more likely in the groups with BMI
25–29 (P¼ 0.01) and X30 (P¼ 0.06). Error bars indicate 95%
confidence intervals.
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note that both left ventricular hypertrophy and dialysis-
related amyloidosis still affect patients receiving longer
thrice-weekly HD treatments,30,31 which makes the case for
these regimens less intuitive and in need of corroboration by
clinical study. Figure 5 suggests that the mechanisms for
improved outcomes with longer sessions may be ameliorated
by smaller body size, although it is unclear in our study as to
whether low BMI was a proxy for malnutrition, inflamma-
tion, or Asian race. The mechanisms responsible for the
relationship between HD session length and mortality risk
demonstrated in this study are impossible to infer from the
ANZDATA Registry. Like most registries, the advantages of
broad-based national-level data are offset by a lack of detail.
A major strength of this study is its external validity.
Studies from around the world analyze populations with
often quite different characteristics. The cohort in this study
has differences but also important similarities to North
American and European hemodialysis populations.32,33 The
Dialysis Outcome and Practice Patterns Study allows for
pertinent comparisons, and Table 5 shows the clinical
characteristics of the North American and European Dialysis
Outcome and Practice Patterns Study cohorts flanking the
period of observation in this study. Of course, differences
between dialysis populations do not preclude generalization
of study findings from one to another. For instance, external
validity of this study will only be compromised if the effect of
HD dose or session length on mortality is modified in any
way by the characteristics that differ between dialysis
populations. Other investigators have formally demonstrated
an interaction between HD dose and both gender and
race,34,35 but not for other variables such as angioaccess type,
etc. The findings in this study pertaining to HD dose should
therefore be generalized cautiously to populations with
different proportions of females and black patients. In
contrast, the findings pertaining to HD session length are
reasonably able to be generalized to other patient popula-
tions, more so perhaps than the previously discussed data
from the Japanese national registry which are regarded by
some opinion leaders to have poor external validity.36
Limitations of this research pertain to study design and
data source. Although ANZDATA Registry data are collected
prospectively, the study design is retrospective and observa-
tional, using an inception cohort that by definition restricts
analyses to patients who have survived at least a year on
dialysis using those parameters that have been collected.
Although associations do not prove causality, observational
research can still contribute potentially important and
beneficial knowledge. Patients numbers are large, and are
not limited to those who fulfil the given inclusion criteria.
These issues are particularly relevant, as major interventional
trials in this area have been criticized for both sample size
and selection.37,38 Moreover, a greater number of individual
HD operating parameters may be examined in observational
survival studies, since their analyses within interventional
trials will be limited by the study protocol. Observational
studies are therefore useful to develop hypotheses for survival
analyses, and shape both the design and interpretation of
randomized controlled interventional trials that can be used
to definitely prove causality.
Statistical adjustments in this study minimize the
confounding effects of measured co-variates on the relation-
ship between HD session length and mortality risk. However,
it is possible that there is still residual confounding from
non-randomized assignment of patients to different HD dose
and session lengths. The use of a shared frailty model
explicitly accounts for ‘center effects’; this technique is the
survival analog of a ‘random effects’ model and gives more
conservative outcomes than other approaches.
The data source for these analyses was a registry, and as a
consequence potentially important variables have been
omitted from our analyses since they are not collected by
the ANZDATA Registry. These include serum chemistries
such as phosphate, calcium, albumin, and also clinical
parameters such as functional status, measured residual renal
function, and left ventricular structure/function. There is also
potential for misclassification of patient co-morbid condi-
tions, since these are based on the opinion of the treating
nephrologist without the benefit of rigorous or standardized
criteria. Finally, standard blood sampling techniques for
Kt/V are recommended by the ANZDATA Registry, but no
audit has been conducted to determine compliance. Vari-
ability in technique may therefore result in measurement
Table 5 | Clinical characteristics of the United States and European hemodialysis cohorts from the DOPPS
United States–DOPPS Europe–DOPPS
Phase 1 (1998) Phase 2 (2002/2003) Phase 1 (1998) Phase 2 (2002/2003)
n 12 126 7028 6109 7313
Mean age (years) 59.5 61.6 60.4 62.9
Male (%) 53 54 57 58
Black (%) 41 34 2 2
Diabetes mellitus as primary cause
of end-stage renal failure (%)
41 48 16 20
Diabetes mellitus (%) 46 53 20 24
Arteriovenous fistula (%) 24 31 80 79
All statistics shown are based upon prevalent cross-sections; Europe–DOPPS for this analysis was comprised of the five European countries participating in both phases
of DOPPS, and these countries were France, Germany, Italy, Spain, and the United Kingdom (personal communication RL Pisoni, 13 August 2005).
DOPPS, Dialysis Outcomes and Practice Patterns Study.
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error for Kt/V, the impact of which is difficult to estimate in
this study.
The findings of this study suggest a randomized controlled
trial to test the influence of HD session duration. The
primary intervention should be randomization for HD
session length of 4.0–4.5 h (hazard ratio 1.0) vs 4.5–5.0 h
(hazard ratio 0.8), with HD dose to be controlled in either
arm such that Kt/V is greater than 1.3. The utilization of a
two-by-two factorial design with a second intervention of
randomization for HD dose is probably not justified on the
basis of the HEMO study. The mortality rate of 9% per year
for our study cohort indicates that a proposed trial would be
of 4 years duration (2 years recruitment and 2 years follow-
up), and that a large sample size of 1757 patients would be
needed to demonstrate a 25% mortality difference with the
primary intervention of HD session length.
In conclusion, this study demonstrates that both HD dose
and session length are independently associated with
mortality risk in Australia and New Zealand patient
populations. This supports the direction of recent and
proposed research involving the prospective study of patient
outcomes with alternative HD schedules.
MATERIALS AND METHODS
Study population
The ANZDATA Registry collects data on all patients with end-stage
renal disease in Australia and New Zealand. Data collection rounds
occur at 6-monthly intervals, at 31 March and 30 September of each
year. End-stage renal disease patients are defined as those with a
diagnosis of chronic renal failure and for whom renal replacement
therapy is intended to be an indefinite treatment. Details of the
structure and methods of the registry have been reported else-
where.23 The data collected include information about the under-
lying primary renal disease, pre-dialysis care, demographic details,
presence of co-morbid medical conditions as indicated by the
treating nephrologist (type I and II diabetes mellitus, coronary
artery disease, peripheral vascular disease, cerebrovascular disease,
chronic lung disease, treated hypertension, current and former
smoking), and the type and details of renal replacement therapy
including angioaccess. Data about HD dose have only been included
since the April 1997 survey. An inception cohort was created by
identifying all incident end-stage renal disease patients age 25 years
or older at commencement of dialysis, treated by thrice-weekly
maintenance HD (on HD both 90 days after commencement and
also at 12 months after dialysis inception) in Australia and New
Zealand between 1 April 1997 and 31 March 2004. Patients were
excluded if they died or changed renal replacement modality within
12 months of HD inception.
Statistical analyses
Follow-up for analysis commenced 12 months after commencement
of renal replacement therapy. HD dose and session length were
included in analyses as that first recorded 12 months after dialysis
inception to minimize confounding from residual renal function.
HD dose was expressed as single-pool fractional clearance of body
water for urea (Kt/V);39 values reported as URR to the ANZDATA
Registry were converted to Kt/V by method of Casino and Basile.40
Patients with reported or calculated Kt/V of less than 0.6 or greater
than 2.4 were excluded from analyses as likely erroneous data.
Primary analysis of Kt/V and session length was performed by
categories. As these parameters are continuous variables, they were
also modelled as fractional polynomial functions.41,42 This techni-
que allows for the fitting of a smooth line or curve without the
artifacts observed with cubic splines, and avoids the problems
associated with arbitrary selection of categories.43,44
Observational data are presented as median (interquartile range)
or number (percentage). Where necessary, comparisons between
groups were made using the Mann–Whitney U-test for continuous
variables, and the w2 test for categorical ones.
The outcome examined was patient mortality, based upon details
provided by the treating unit. HD treatment was censored at the
time of transplantation. Survival analyses included Kaplan–Meier
calculations of survival and Cox regression for multivariate analyses.
Cox models were stratified by year of dialysis commencement. The
covariates included in the Cox models were age, gender, race,
primary renal disease, calculated creatinine clearance at dialysis
inception,45 late referral for nephrology pre-dialysis care (o3
months before commencement of renal replacement therapy), type I
and II diabetes mellitus, and presence of the above co-morbid
conditions at commencement of dialysis. For reported co-morbid-
ities, ‘suspected’ was included with ‘yes’ for analyses. Angioaccess
type (native fistula, prosthetic bridge graft, tunnelled and untun-
nelled central venous catheter) and hemodialyzer flux were included
in analyses as that first recorded as being in use 12 months after
dialysis inception. BMI was modelled as a categorical variable (o20,
20–24.9, 25–29.9, and 430 kg/m2) using recorded height at, and
weight 12 months after, dialysis inception. Hemoglobin was not
included in analyses since these data have only been collected since 1
October 2000. Hemodialyzer reuse also was not included as this
practice is extremely rare in Australia and New Zealand. Follow-up
was determined to 31 March 2004. Multivariate models initially
included all of the covariates; those with P40.05 were dropped in a
backward stepwise manner. All models included a gamma-
distributed shared frailty, using the hospital of initial treatment as
the group. Potential interactions were sought using likelihood ratio
tests.
Statistical significance was attributed to findings if the two-tailed
P-value was o0.05. All analyses were undertaken using Intercooled
Stata 8.2 (StataCorp, College Station, TX, USA).
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